Hamama (HMAM) fair value: what the stock is really worth
As of Sep 16, 2026: fair value of Hamama ILS 2.90, price ILS 5.32, upside -45.6%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Hamama for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 2.17 ILA – 7.89 ILA · fair‑value band 2.19 ILA – 4.12 ILA · the 5.32 ILA price screens above the 2.90 ILA fair value. 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Hamama in your weekly email
Every Wednesday you see whether Hamama is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hamama Meir Trading (1996) Ltd. engages in the import, marketing, and distribution of raw materials for the food industry in Israel and internationally.
Show more
Hamama Meir Trading (1996) Ltd. engages in the import, marketing, and distribution of raw materials for the food industry in Israel and internationally. The company offers grains, pulses, nuts, dried fruits, seeds and herbs, coffee, rice, chickpeas, beans, sunflower and pumpkin seeds, cashews, pistachios, raw sesame and peeled sesame seeds, cereals, oil, and animal feed. It serves food manufacturers, wholesalers, roasters, packaging houses, mixing plants, and institutional customers. Hamama Meir Trading (1996) Ltd. was incorporated in 1996 and is headquartered in Bnei Brak, Israel.
Stock analysis
Hamama (HMAM) currently trades at 5.32 ILA, while our model-based Fair Value estimate is 2.90 ILA, implying the stock looks roughly 83.8% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 21.49 ILA per share, and 12 of the 13 models we run sit above the 5.32 ILA price.
Bear case: the Asset-Based group reads lowest at 5.05 ILA, and 1 of the 13 models stay below the price. Evidence for this calculation is medium.
Scenario range: 2.19 ILA (bear) to 4.12 ILA (bull), the price of 5.32 ILA sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Hamama reported revenue of 250M ILS in FY2025 versus 277M ILS in FY2021, a compound −2.6%/yr. Reported net income was 14.9M ILS in FY2025, compounding −1.8%/yr from FY2021.
Key figures
Market cap 75.5M ILA · P/E ratio 5.1 · P/S ratio 0.30 · EPS (TTM) 1.05 ILA · Net margin 6.0% · Return on equity 15.0% · Return on assets (EBIT) 5.7% · Operating margin 3.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 10% fair-value upside, at −46%, HMAM screens richer than that median.
Fair Value models
Bear 2.19 ILAFair Value 2.90 ILABull 4.12 ILA
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.7710 ILS per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.26/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Start year 2020 (pandemic). Over 10 years: −6.4% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+16.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+16.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.8% vs 12%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 6%
2025 sits 292% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 7.1%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Farm Products · 296 stocks
Beats the industry median on 8/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−46% · Bottom 25%
Profitability
Return on equity (TTM)15% · Top 25%
Return on assets5% · Above median
Net margin (TTM)6% · Above median
Operating margin (TTM)4% · Below median
Growth and dividend
Revenue growth6% · Above median
Valuation Multiplesvs Farm Products median · lower = cheaper
P/E (TTM)5.1× · Cheapest 25%
P/B0.23× · Cheapest 25%
P/S (TTM)0.10× · Cheapest 25%
EV/EBITDA1.3× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 34
FUTURE (revenue growth)30· sector 21
PAST (return on equity)60· sector 19
HEALTH (low debt)100· sector 94
DIVIDEND (yield)0· sector 47
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hamama Fair Value". https://www.fairvalue-calculator.com/stock/HMAM
Frequently asked questions
Is Hamama (HMAM) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2.90 ILA versus the last price from Sep 16, 2026 of 5.32 ILA, about −46% upside (overvalued).
What is the fair value of HMAM?
Our model-based fair value for Hamama is 2.90 ILA (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 16, 2026): 5.32 ILA.
What is the quality score of HMAM?
Hamama has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hamama (HMAM)?
Our model-based price target is the fair value of 2.90 ILA (as of Sep 24, 2026) from 13 valuation models. Cautious scenario 2.19 ILA, optimistic scenario 4.12 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Hamama stock forecast for 2026?
Our models put fair value at 2.90 ILA, about −46% upside versus the last price from Sep 16, 2026 of 5.32 ILA (overvalued). Cautious scenario 2.19 ILA, optimistic scenario 4.12 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Hamama (HMAM)?
Hamama reported trailing-twelve-month revenue of about 250M ILS (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Hamama (HMAM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hamama it is 2.90 ILA per share (as of Sep 24, 2026), against a price of 5.32 ILA. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Hamama stock overvalued or undervalued in 2026?
As of Sep 24, 2026, HMAM trades above its calculated fair value: price 5.32 ILA, fair value 2.90 ILA, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HMAM?
No. The price is what the market pays today (5.32 ILA); the fair value is what the company's own numbers justify (2.90 ILA). For Hamama the two are 2.43 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Hamama worth?
The market values Hamama at about 75.5M ILA (market capitalisation, as of Sep 24, 2026). Per share that is 5.32 ILA; our models calculate a fair value of 2.90 ILA per share.
What do the bullish and bearish scenarios say about HMAM?
Our models span a range for Hamama: cautious scenario 2.19 ILA, base 2.90 ILA, optimistic 4.12 ILA per share (as of Sep 24, 2026, price 5.32 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HMAM?
Hamama trades at a price-to-earnings ratio of 5.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2.90 ILA is built from several models across several years. Other multiples: P/B 0.2, P/S 0.1, EV/EBITDA 1.3.
How solid is the balance sheet of Hamama (HMAM)?
Balance-sheet figures for Hamama (as of Sep 24, 2026): return on equity 15.0%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is HMAM from its 52-week high?
Hamama trades at 5.32 ILA, about 32% below its 52-week high of 7.80 ILA and 3% above the low of 5.18 ILA (as of Sep 16, 2026). Distance from the high says nothing about value: that is what the fair value of 2.90 ILA is for.
Which stocks are comparable to Hamama?
From the same area (Consumer Defensive) we also value Archer-Daniels-Midland Company, Muyuan Foods Group, Bunge Global SA, Tyson Foods, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hamama stock attractive at the current price?
The data as of Sep 24, 2026: price 5.32 ILA, calculated fair value 2.90 ILA (−46%), Quality Score 52/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HMAM calculated?
We run Hamama through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2.90 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Hamama itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hamama (HMAM)?
The latest price we hold is from Sep 16, 2026 and stands at 5.32 ILA. Our model-based fair value is 2.90 ILA, about −46% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hamama right now?
The price sits above even our optimistic bull case (4.12 ILA). The favourable scenario is already priced in. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (2.19 ILA to 4.12 ILA) leaves room in how you read the outcome.
Key figures of Hamama
How large is the market capitalisation of Hamama (HMAM)?
The market capitalisation of Hamama is 75.5M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hamama (HMAM)?
The price-to-sales ratio of Hamama is 0.30 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hamama (HMAM)?
Earnings per share at Hamama are 1.05 ILA (price ÷ EPS = P/E 5.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hamama (HMAM)?
The net margin of Hamama is 6.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hamama (HMAM)?
The return on equity (ROE) of Hamama is 15.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hamama (HMAM)?
On an EBIT basis the return on assets of Hamama is 5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hamama (HMAM)?
The operating margin of Hamama is 3.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hamama (HMAM)?
Revenue at Hamama is growing +5.9% versus a year earlier (3y avg −5.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hamama (HMAM)?
Earnings per share at Hamama are growing +97.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hamama (HMAM) generate?
The free cash flow of Hamama is −7.7M ILA (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hamama (HMAM) carry?
The net debt of Hamama is 32.6M ILA (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hamama in the live analysis
One click puts Hamama on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
